March 09, 2014
(Stock Blog Hub, 1/16/13)
ArQule Inc. (ARQL) and partner Daiichi Sankyo recently announced disappointing phase II results on oncology candidate, tivantinib (ARQ 197). The study evaluated...(read more)
(Stock Blog Hub, 1/18/12)
• Bio technology company ArQule Inc.’s (NASDAQ:ARQL) share prices gained 11.91% to close at $6.67 after the company's experimental treatment for liver cancer...(read more)
ArQule, Inc. (Nasdaq: ARQL) today announced a Special Protocol Assessment agreement with the U.S. Food and Drug Administration for the design of a Phase 3 trial of ARQ 197 in patients with non-small cell lung cancer of non-squamous...(read more)
ArQule (ARQL) Company Overview
There is no analysis for ARQL yet. But you can go to Wikinvest to help create one!